Advertisement

The expression of serotonin transporter protein in the skin of patients with chronic spontaneous urticaria and its relation with depression and anxiety

  • Naghmeh Zabolinejad
  • Sara Molkara
  • Behnoosh Bakhshodeh
  • Haniyeh Ghaffari-Nazari
  • Maryam KhoshkhuiEmail author
Original Paper
  • 1 Downloads

Abstract

Studies have indicated a possible role for serotonin transporter protein (SERT) in the pathophysiology of inflammatory skin disorders. This study was aimed to determine the expression of SERT in the skin of patients with chronic spontaneous urticaria (CSU) and its relation to depression and anxiety. In this case–control study, 30 CSU patients and 30 healthy controls were evaluated with skin biopsies to evaluate the expression of the SERT protein based on histopathologic findings. Beck depression and anxiety inventories were used to investigate depression and anxiety in the case group. Data were analyzed by SPSS software. P values < 0.05 were considered significant. The case group showed significantly higher percentage of stained cells (P < 0.0001) and intensity of SERT expression (P < 0.0001) compared with the control group. The patients with uncontrolled CSU showed significantly higher percentage (P < 0.002) and intensity (P < 0.006) of SERT expression, compared with those with controlled CSU. The intensity of SERT expression in CSU patients had no significant correlation with the severity of depression, but was significantly correlated with the severity of anxiety (r = 0.555; P = 0.001). The percentage of stained cells was significantly correlated with the severities of depression (r = − 0.433; P = 0.017) and anxiety (r = 0.528; P = 0.003). The SERT expression in patients with CSU was higher compared with controls, which can demonstrate the role of serotonin in the pathogenesis of this disease. This higher SERT expression is correlated with the severity of the disease.

Keywords

Chronic spontaneous urticaria Serotonin transporter protein Anxiety Depression 

Notes

Acknowledgements

The authors wish to thank the Vice Chancellor for Research of Mashhad University of Medical Sciences for their financial support.

Funding

This project was part of a thesis by Dr. Sara Molkara (Grant number: 951756), supported by a Grant from the Vice Chancellor for Research of Mashhad University of Medical Sciences.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

All procedures involving human participants were in accordance with the ethical standards of the national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the ethics committee of Mashhad University of Medical Sciences (Registered no.: MUMS.fm.REC.1396.531).

Informed consent

Informed consent was obtained from all individuals who participated in the study.

References

  1. 1.
    Arreola R, Becerril-Villanueva E, Cruz-Fuentes C, Velasco-Velázquez MA, Garcés-Alvarez ME, Hurtado-Alvarado G, Quintero-Fabian S, Pavón L (2015) Immunomodulatory effects mediated by serotonin. J Immunol ResGoogle Scholar
  2. 2.
    Canli T, Lesch K-P (2007) Long story short: the serotonin transporter in emotion regulation and social cognition. Nat Neurosci 10:1103CrossRefGoogle Scholar
  3. 3.
    Darlenski R, Kazandjieva J, Zuberbier T, Tsankov N (2014) Chronic urticaria as a systemic disease. Clin Dermatol 32:420–423CrossRefGoogle Scholar
  4. 4.
    DeLong LK, Culler SD, Saini SS, Beck LA, Chen SC (2008) Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol 144:35–39CrossRefGoogle Scholar
  5. 5.
    Demera RS, Ryhal B, Gershwin ME (2001) Chronic idiopathic urticaria. Comp Ther 27:213–217CrossRefGoogle Scholar
  6. 6.
    El-Nour H, Lundeberg L, Abdel-Magid N, Lonne-Rahm S-B, Azmitia CE, Nordlind K (2007) Serotonergic mechanisms in human allergic contact dermatitis. Acta Dermato-venereol 87:390–396CrossRefGoogle Scholar
  7. 7.
    Engin B, Uguz F, Yilmaz E, Özdemir M, Mevlitoglu I (2008) The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 22:36–40Google Scholar
  8. 8.
    Eskeland S, Halvorsen JA, Tanum L (2017) Antidepressants have anti-inflammatory effects that may be relevant to dermatology: a systematic review. Acta Dermato-venereol 97:897–905CrossRefGoogle Scholar
  9. 9.
    Eskeland S, Tanum L, Halvorsen J (2016) Delayed pressure urticaria treated with the selective serotonin reuptake inhibitor escitalopram. Clin Exp Dermatol 41:526–528CrossRefGoogle Scholar
  10. 10.
    Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N (2005) Psychometric properties of a Persian-language version of the Beck Depression Inventory-Second edition: BDI-II-PERSIAN. Depress Anxiety 21:185–192CrossRefGoogle Scholar
  11. 11.
    Goyonlo VM, Elnour H, Nordlind K (2014) Serotonin transporter protein overexpression and association to Th 17 and T regulatory cells in lupoid leishmaniasis. Arch Dermatol Res 306:181–188CrossRefGoogle Scholar
  12. 12.
    Greaves MW (2003) Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 3:363–368CrossRefGoogle Scholar
  13. 13.
    Gupta M, Gupta A (1995) Chronic idiopathic urticaria associated with panic disorder: a syndrome responsive to selective serotonin reuptake inhibitor antidepressants? Cutis 56:53–54Google Scholar
  14. 14.
    Hashiro M, Okumura M (1994) Anxiety, depression, psychosomatic symptoms and autonomic nervous function in patients with chronic urticaria. J Dermatol Sci 8:129–135CrossRefGoogle Scholar
  15. 15.
    Hergüner S, Kılıç G, Karakoc S, Tamay Z, Tüzün Ü, Güler N (2011) Levels of depression, anxiety and behavioural problems and frequency of psychiatric disorders in children with chronic idiopathic urticaria. Br J Dermatol 164:1342–1347CrossRefGoogle Scholar
  16. 16.
    Kaviani H, Mousavi A (2008) Psychometric properties of the Persian version of Beck Anxiety Inventory (BAI). Tehran Univ Med J TUMS Publ 66:136–140Google Scholar
  17. 17.
    Kim K (2012) Neuroimmunological mechanism of pruritus in atopic dermatitis focused on the role of serotonin. Biomol Ther 20:506CrossRefGoogle Scholar
  18. 18.
    Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M (2017) Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol 139(1772–1781):e1771Google Scholar
  19. 19.
    Kretschmer T, Sentse M, Dijkstra JK, Veenstra R (2014) The interplay between peer rejection and acceptance in preadolescence and early adolescence, serotonin transporter gene, and antisocial behavior in late adolescence: the TRAILS study. Merrill Palmer Q (1982) 60:193–216CrossRefGoogle Scholar
  20. 20.
    Kritas S, Saggini A, Cerulli G, Caraffa A, Antinolfi P, Pantalone A, Rosati M, Tei M, Speziali A, Saggini R (2014) Relationship between serotonin and mast cells: inhibitory effect of anti-serotonin. J Biol Regul Homeost Agents 28:377–380Google Scholar
  21. 21.
    Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S (2007) Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 34:294–301CrossRefGoogle Scholar
  22. 22.
    Leonard BE, Myint A (2009) The psychoneuroimmunology of depression. Hum Psychopharmacol Clin Exp 24:165–175Google Scholar
  23. 23.
    Lonne-Rahm SB, Rickberg H, El-Nour H, Mårin P, Azmitia E, Nordlind K (2008) Neuroimmune mechanisms in patients with atopic dermatitis during chronic stress. J Eur Acad Dermatol Venereol 22:11–18CrossRefGoogle Scholar
  24. 24.
    Maniaci G, Epifanio M, Marino M, Amoroso S (2006) The presence of alexithymia investigated by the TAS-20 in chronic urticaria patients: a preliminary report. Eur Ann Allergy Clin Immunol 38:15–19Google Scholar
  25. 25.
    Mann JJ, Huang Y-y, Underwood MD, Kassir SA, Oppenheim S, Kelly TM, Dwork AJ, Arango V (2000) A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 57:729–738CrossRefGoogle Scholar
  26. 26.
    Mössner R, Lesch K-P (1998) Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 12:249–271CrossRefGoogle Scholar
  27. 27.
    Nordlind K, Azmitia EC, Slominski A (2008) The skin as a mirror of the soul: exploring the possible roles of serotonin. Exp Dermatol 17:301–311CrossRefGoogle Scholar
  28. 28.
    Ogilvie AD, Battersby S, Fink G, Harmar A, Goodwin G, Bubb V, Smith CD (1996) Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347:731–733CrossRefGoogle Scholar
  29. 29.
    Özkan M, Oflaz SB, Kocaman N, Özşeker F, Gelincik A, Büyüköztürk S, Özkan S, Çolakoğlu B (2007) Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 99:29–33CrossRefGoogle Scholar
  30. 30.
    Petito A, Altamura M, Iuso S, Padalino FA, Sessa F, D'Andrea G, Margaglione M, Bellomo A (2016) The relationship between personality traits, the 5HTT polymorphisms, and the occurrence of anxiety and depressive symptoms in elite athletes. PLoS ONE 11:e0156601CrossRefGoogle Scholar
  31. 31.
    Picardi A, Abeni D, Melchi C, Puddu P, Pasquini P (2000) Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 143:983–991CrossRefGoogle Scholar
  32. 32.
    Risch N, Herrell R, Lehner T, Liang K-Y, Eaves L, Hoh J, Griem A, Kovacs M, Ott J, Merikangas KR (2009) Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 301:2462–2471CrossRefGoogle Scholar
  33. 33.
    Ronpirin C, Tencomnao T (2010) Psoriasis: a review of the role of serotonergic system. Afr J Biotech 9:1528–1534CrossRefGoogle Scholar
  34. 34.
    Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R (2010) Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum 62:683–693CrossRefGoogle Scholar
  35. 35.
    Schinka JA, Busch RM, Robichaux-Keene N (2004) A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol Psychiatry 9:197.  https://doi.org/10.1038/sj.mp.4001405 CrossRefGoogle Scholar
  36. 36.
    Shah B, Levenson JL (2018) Use of psychotropic drugs in the dermatology patient: when to start and stop? Clin Dermatol 36:748–755CrossRefGoogle Scholar
  37. 37.
    Slominski A, Wortsman J (2000) Neuroendocrinology of the skin. Endocr Rev 21:457–487Google Scholar
  38. 38.
    Slominski A, Wortsman J, Paus R, Elias PM, Tobin DJ, Feingold KR (2008) Skin as an endocrine organ: implications for its function. Drug Discov Today Dis Mech 5:e137–e144CrossRefGoogle Scholar
  39. 39.
    Slominski A, Wortsman J, Tobin DJ (2005) The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J 19:176–194CrossRefGoogle Scholar
  40. 40.
    Staubach P, Eckhardt-Henn A, Dechene M, Vonend A, Metz M, Magerl M, Breuer P, Maurer M (2006) Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 154:294–298CrossRefGoogle Scholar
  41. 41.
    Thorslund K, Amatya B, Dufva AE, Nordlind K (2013) The expression of serotonin transporter protein correlates with the severity of psoriasis and chronic stress. Arch Dermatol Res 305:99–104CrossRefGoogle Scholar
  42. 42.
    Thorslund K, El-Nour H, Nordlind K (2009) The serotonin transporter protein is expressed in psoriasis, where it may play a role in regulating apoptosis. Arch Dermatol Res 301:449–457CrossRefGoogle Scholar
  43. 43.
    Thorslund K, Nordlind K (2007) Serotonergic drugs—a possible role in the treatment of psoriasis. Drug News Perspect 20:521–525CrossRefGoogle Scholar
  44. 44.
    Thorslund K, Svensson T, Nordlind K, Ekbom A, Fored C (2013) Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: a population-based cohort study. J Intern Med 274:281–287CrossRefGoogle Scholar
  45. 45.
    Uguz F, Engin B, Yilmaz E (2008) Axis I and Axis II diagnoses in patients with chronic idiopathic urticaria. J Psychosom Res 64:225–229CrossRefGoogle Scholar
  46. 46.
    Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, Martus P, Casale TB, Staubach P, Maurer M (2014) Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 133:1365.e1366–1372.e1366CrossRefGoogle Scholar
  47. 47.
    Willis-Owen SA, Turri MG, Munafò MR, Surtees PG, Wainwright NW, Brixey RD, Flint J (2005) The serotonin transporter length polymorphism, neuroticism, and depression: a comprehensive assessment of association. Biol Psychiatr 58:451–456CrossRefGoogle Scholar
  48. 48.
    Yasharpour MR, Randhawa I (2011) Antidepressants in chronic idiopathic urticaria. In: Allergy and asthma proceedings, vol 6Google Scholar
  49. 49.
    Ye Y-M, Kim BE, Shin YS, Park H-S, Leung DY (2014) Increased epidermal filaggrin in chronic idiopathic urticaria is associated with severity of urticaria. Ann Allergy Asthma Immunol 112:533–538CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Cutaneous Leishmaniasis Research Center, Mashhad University of Medical SciencesMashhadIran
  2. 2.Student Research CommitteeMashhad University of Medical SciencesMashhadIran
  3. 3.Immunogenetic and Cell Culture Department, Immunology Research Center, School of MedicineMashhad University of Medical SciencesMashhadIran
  4. 4.Allergy Research CenterMashhad University of Medical SciencesMashhadIran

Personalised recommendations